BACKGROUND/AIMS: Transcatheter arterial chemoembolization (TACE) has been shown to increase survival in @entity1 with unresectable @entity157 ( @entity157 ), however @entity137 from commonly used agents limits its use in unresectable disease. @entity136 is a well tolerated chemotherapeutic agent with a high first pass clearance. In this study we evaluated a cohort of @entity1 with unresectable @entity157 treated with @entity136 -TACE alone. METHODOLOGY: A review of all @entity1 that underwent @entity136 -TACE for unresectable @entity157 from 2002 to 2006 was performed. No @entity1 were eligible for resection, liver transplantation or ablation. All @entity1 received @entity136 -TACE alone. The primary outcome measure was survival from first treatment. Secondary outcome measures included radiological response and @entity137 . RESULTS: 55 @entity1 underwent a total of 172 @entity136 -TACE treatments for unresectable @entity157 . Median age was 64.7 years. All @entity1 had @entity96 ( @entity96 ) stage B (44%) or C (56%) disease. Median survival following @entity136 -TACE was 8.8 months. 22% demonstrated a partial response and 61% had stable disease. 6% experienced grade 3/4 adverse events. There was 1 treatment related @entity204 . CONCLUSIONS: @entity136 -TACE is well tolerated and appears to provide an alternative agent for @entity1 with unresectable @entity157 undergoing chemoembolization.

@entity136 transcatheter arterial chemoembolization for unresectable XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity96 :: ('MESH:D008113', 'Disease') :: ['Barcelona-Clinic Liver Cancer', 'BCLC'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['Gemcitabine', 'gemcitabine']
@entity157 :: (MESH:D006528,Disease) :: ['hepatocellular carcinoma']
